Precision Biologics to Announce Development of New Monoclonal Antibody (mAb) PB-223 at SITC, Houston, TX, November 7-8, 2024
Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...
Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...
Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel...
Precision Biologics announces the filing of a new patent for our second asset, PB-233. This...
Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...
Precision Biologics awarded new US Patent on its lead monoclonal antibody NEO-201 for regulatory T-cell...
Precision Biologics presents new data from ongoing clinical trial combining NEO-201 with pembrolizumab at the...
7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 - May 1, 2024 Accelerating Robust, Durable &...
IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024 Day 1: Track 1: Discovery & Development:...
Precision Biologics will present recent scientific data at the American Association for Cancer Research (AACR)...